Annual FCF
-$1.61 M
+$65.55 M+97.61%
31 December 2023
Summary:
EyePoint Pharmaceuticals annual free cash flow is currently -$1.61 million, with the most recent change of +$65.55 million (+97.61%) on 31 December 2023. During the last 3 years, it has risen by +$13.19 million (+89.13%). EYPT annual FCF is now -115.86% below its all-time high of $10.14 million, reached on 30 June 2015.EYPT Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
-$40.60 M
-$19.52 M-92.63%
30 September 2024
Summary:
EyePoint Pharmaceuticals quarterly free cash flow is currently -$40.60 million, with the most recent change of -$19.52 million (-92.63%) on 30 September 2024. Over the past year, it has dropped by -$23.68 million (-139.91%). EYPT quarterly FCF is now -171.70% below its all-time high of $56.63 million, reached on 30 June 2023.EYPT Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
-$118.04 M
-$23.68 M-25.09%
30 September 2024
Summary:
EyePoint Pharmaceuticals TTM free cash flow is currently -$118.04 million, with the most recent change of -$23.68 million (-25.09%) on 30 September 2024. Over the past year, it has dropped by -$127.25 million (-1381.48%). EYPT TTM FCF is now -1054.61% below its all-time high of $12.37 million, reached on 31 December 2014.EYPT TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
EYPT Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +97.6% | -139.9% | -1381.5% |
| 3 y3 years | +89.1% | -412.8% | -323.3% |
| 5 y5 years | +92.9% | -174.9% | -159.9% |
EYPT Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +97.6% | -171.7% | at low | -1100.2% | at low |
| 5 y | 5 years | at high | +97.6% | -171.7% | at low | -1100.2% | at low |
| alltime | all time | -115.9% | +97.6% | -171.7% | at low | -1054.6% | at low |
EyePoint Pharmaceuticals Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$40.60 M(+92.6%) | -$118.04 M(+25.1%) |
| June 2024 | - | -$21.08 M(-34.9%) | -$94.36 M(+466.6%) |
| Mar 2024 | - | -$32.37 M(+34.9%) | -$16.65 M(+935.7%) |
| Dec 2023 | -$1.61 M(-97.6%) | -$23.99 M(+41.8%) | -$1.61 M(-117.5%) |
| Sept 2023 | - | -$16.92 M(-129.9%) | $9.21 M(-21.9%) |
| June 2023 | - | $56.63 M(-427.0%) | $11.80 M(-118.4%) |
| Mar 2023 | - | -$17.32 M(+31.5%) | -$64.17 M(-4.4%) |
| Dec 2022 | -$67.16 M(+33.6%) | -$13.17 M(-8.1%) | -$67.16 M(-4.9%) |
| Sept 2022 | - | -$14.33 M(-25.9%) | -$70.65 M(+10.0%) |
| June 2022 | - | -$19.34 M(-4.8%) | -$64.23 M(+15.8%) |
| Mar 2022 | - | -$20.31 M(+21.8%) | -$55.46 M(+10.4%) |
| Dec 2021 | -$50.25 M(+239.6%) | -$16.67 M(+110.5%) | -$50.25 M(+80.2%) |
| Sept 2021 | - | -$7.92 M(-25.1%) | -$27.88 M(+47.1%) |
| June 2021 | - | -$10.57 M(-30.0%) | -$18.96 M(+40.1%) |
| Mar 2021 | - | -$15.10 M(-364.8%) | -$13.54 M(-8.5%) |
| Dec 2020 | -$14.80 M(-74.0%) | $5.70 M(+465.8%) | -$14.80 M(-53.7%) |
| Sept 2020 | - | $1.01 M(-119.6%) | -$31.99 M(-33.0%) |
| June 2020 | - | -$5.15 M(-68.5%) | -$47.77 M(-20.1%) |
| Mar 2020 | - | -$16.36 M(+42.4%) | -$59.76 M(+5.0%) |
| Dec 2019 | -$56.91 M(+150.5%) | -$11.49 M(-22.2%) | -$56.91 M(+25.3%) |
| Sept 2019 | - | -$14.77 M(-13.8%) | -$45.42 M(+6.8%) |
| June 2019 | - | -$17.13 M(+26.8%) | -$42.52 M(+34.9%) |
| Mar 2019 | - | -$13.52 M(+13.8%) | -$31.52 M(+13.1%) |
| Dec 2018 | -$22.72 M(+3.2%) | - | - |
| Sept 2018 | - | -$11.88 M(+93.8%) | -$27.86 M(+26.5%) |
| June 2018 | -$22.02 M(+6.7%) | -$6.13 M(+27.1%) | -$22.02 M(+7.6%) |
| Mar 2018 | - | -$4.82 M(-4.3%) | -$20.47 M(+1.3%) |
| Dec 2017 | - | -$5.04 M(-16.5%) | -$20.21 M(+0.1%) |
| Sept 2017 | - | -$6.03 M(+31.8%) | -$20.18 M(-2.2%) |
| June 2017 | -$20.64 M(+25.6%) | -$4.58 M(+0.4%) | -$20.64 M(+0.9%) |
| Mar 2017 | - | -$4.56 M(-9.1%) | -$20.45 M(+1.1%) |
| Dec 2016 | - | -$5.01 M(-22.7%) | -$20.23 M(+9.9%) |
| Sept 2016 | - | -$6.49 M(+47.6%) | -$18.41 M(+12.1%) |
| June 2016 | -$16.43 M(-262.1%) | -$4.39 M(+1.4%) | -$16.43 M(+8.6%) |
| Mar 2016 | - | -$4.33 M(+35.4%) | -$15.13 M(+2.3%) |
| Dec 2015 | - | -$3.20 M(-29.0%) | -$14.80 M(-253.6%) |
| Sept 2015 | - | -$4.50 M(+45.5%) | $9.63 M(-5.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2015 | $10.14 M(-192.8%) | -$3.10 M(-22.5%) | $10.14 M(-1.3%) |
| Mar 2015 | - | -$4.00 M(-118.8%) | $10.27 M(-16.9%) |
| Dec 2014 | - | $21.23 M(-630.7%) | $12.37 M(-211.1%) |
| Sept 2014 | - | -$4.00 M(+35.2%) | -$11.13 M(+2.0%) |
| June 2014 | -$10.92 M(+23.9%) | -$2.96 M(+55.2%) | -$10.92 M(-3.9%) |
| Mar 2014 | - | -$1.91 M(-16.0%) | -$11.36 M(-0.6%) |
| Dec 2013 | - | -$2.27 M(-40.0%) | -$11.43 M(+4.2%) |
| Sept 2013 | - | -$3.79 M(+11.4%) | -$10.97 M(+24.5%) |
| June 2013 | -$8.81 M(-6.3%) | -$3.40 M(+72.1%) | -$8.81 M(+21.4%) |
| Mar 2013 | - | -$1.98 M(+8.9%) | -$7.26 M(-2.5%) |
| Dec 2012 | - | -$1.81 M(+11.6%) | -$7.45 M(-8.7%) |
| Sept 2012 | - | -$1.63 M(-11.9%) | -$8.15 M(-13.4%) |
| June 2012 | -$9.41 M(+184.8%) | -$1.84 M(-14.7%) | -$9.41 M(+47.4%) |
| Mar 2012 | - | -$2.16 M(-14.2%) | -$6.38 M(+9.2%) |
| Dec 2011 | - | -$2.52 M(-12.6%) | -$5.84 M(+47.7%) |
| Sept 2011 | - | -$2.88 M(-344.2%) | -$3.96 M(+19.8%) |
| June 2011 | -$3.30 M(-133.4%) | $1.18 M(-172.7%) | -$3.30 M(-136.2%) |
| Mar 2011 | - | -$1.62 M(+156.2%) | $9.13 M(-1.7%) |
| Dec 2010 | - | -$633.00 K(-71.6%) | $9.29 M(+8.0%) |
| Sept 2010 | - | -$2.23 M(-116.4%) | $8.60 M(-13.2%) |
| June 2010 | $9.88 M(-214.5%) | $13.61 M(-1031.4%) | $9.90 M(-303.3%) |
| Mar 2010 | - | -$1.46 M(+10.4%) | -$4.87 M(-7.8%) |
| Dec 2009 | - | -$1.32 M(+43.0%) | -$5.28 M(+6.4%) |
| Sept 2009 | - | -$925.00 K(-20.3%) | -$4.96 M(-42.5%) |
| June 2009 | -$8.63 M(+59.4%) | -$1.16 M(-37.9%) | -$8.63 M(-14.1%) |
| Mar 2009 | - | -$1.87 M(+86.0%) | -$10.05 M(-4135.7%) |
| Dec 2008 | - | -$1.01 M(-78.1%) | $249.00 K(-104.4%) |
| Sept 2008 | - | -$4.59 M(+78.1%) | -$5.66 M(+4.6%) |
| June 2008 | -$5.42 M(-74.6%) | -$2.58 M(-130.6%) | -$5.42 M(+90.9%) |
| Mar 2008 | - | $8.43 M(-221.8%) | -$2.84 M(-74.8%) |
| Dec 2007 | - | -$6.92 M(+59.2%) | -$11.26 M(+159.2%) |
| Sept 2007 | - | -$4.35 M | -$4.35 M |
| June 2007 | -$21.30 M(+23.2%) | - | - |
| June 2006 | -$17.29 M(+44.9%) | - | - |
| June 2005 | -$11.93 M(+105.7%) | - | - |
| June 2004 | -$5.80 M(+87.4%) | - | - |
| June 2003 | -$3.10 M(+591.0%) | - | - |
| June 2001 | -$448.00 K | - | - |
FAQ
- What is EyePoint Pharmaceuticals annual free cash flow?
- What is the all time high annual FCF for EyePoint Pharmaceuticals?
- What is EyePoint Pharmaceuticals annual FCF year-on-year change?
- What is EyePoint Pharmaceuticals quarterly free cash flow?
- What is the all time high quarterly FCF for EyePoint Pharmaceuticals?
- What is EyePoint Pharmaceuticals quarterly FCF year-on-year change?
- What is EyePoint Pharmaceuticals TTM free cash flow?
- What is the all time high TTM FCF for EyePoint Pharmaceuticals?
- What is EyePoint Pharmaceuticals TTM FCF year-on-year change?
What is EyePoint Pharmaceuticals annual free cash flow?
The current annual FCF of EYPT is -$1.61 M
What is the all time high annual FCF for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals all-time high annual free cash flow is $10.14 M
What is EyePoint Pharmaceuticals annual FCF year-on-year change?
Over the past year, EYPT annual free cash flow has changed by +$65.55 M (+97.61%)
What is EyePoint Pharmaceuticals quarterly free cash flow?
The current quarterly FCF of EYPT is -$40.60 M
What is the all time high quarterly FCF for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals all-time high quarterly free cash flow is $56.63 M
What is EyePoint Pharmaceuticals quarterly FCF year-on-year change?
Over the past year, EYPT quarterly free cash flow has changed by -$23.68 M (-139.91%)
What is EyePoint Pharmaceuticals TTM free cash flow?
The current TTM FCF of EYPT is -$118.04 M
What is the all time high TTM FCF for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals all-time high TTM free cash flow is $12.37 M
What is EyePoint Pharmaceuticals TTM FCF year-on-year change?
Over the past year, EYPT TTM free cash flow has changed by -$127.25 M (-1381.48%)